Replies to post #109214 on Biotech Values

[jq1234]

It's not semantic. Look at Denosumab study endpoint in HRPC, it is time to skeletal-related events (SREs). EXEL184 won't be tested this way, it is for cancer treatment, with OS endpoint likely. They are not comparable.